AlzeCure gets abstract on the Alzstatin platform against Alzheimer's accepted for poster presentation at CTAD
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company has received an abstract approved for poster presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year will be held completely digitally on November 4-7.The abstract, titled Gamma-secretase modulators show selectivity for gamma-secretase-mediated amyloid precursor protein intramembrane